Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

CONCLUSION: The inclusion of ARAT agents was associated with a significantly higher risk of several CVAEs. Clinicians should remain vigilant, both in pre-treatment screening and monitoring for clinical symptoms and signs, when considering ARAT agent particularly for patients with pre-existing risk factors.PMID:38584004 | DOI:10.1016/j.clgc.2024.102066

Source: Clinical Prostate Cancer - April 7, 2024 Category: Cancer & Oncology Authors: Susu Zhou Parissa Alerasool Noriko Kishi Himanshu Joshi Gagan Sahni Che-Kai Tsao Source Type: research